QuickView for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=9110FD15068299806EFF710501DE51E1;jsessionid=D1B02C1214DECE22545BE81AEDC29B6F;jsessionid=45AB13D9128A3D4236A7418FD4B00515;jsessionid=CD073BDF0E47A0A5959070E634F65366;jsessionid=2B2D46EB21CE0CC25367A0D788A1C916;jsessionid=E3ABCC38B2DFB44B1D6D02FE29D50CDD (gene)

1. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistan…
2. Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged wild-type mice.
3. Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Mat…
4. A chemical compound inhibiting the Aha1-Hsp90 chaperone complex.
5. Cooperative Nucleotide Binding in Hsp90 and Its Regulation by Aha1.

There were no clinical trials for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=9110FD15068299806EFF710501DE51E1;jsessionid=D1B02C1214DECE22545BE81AEDC29B6F;jsessionid=45AB13D9128A3D4236A7418FD4B00515;jsessionid=CD073BDF0E47A0A5959070E634F65366;jsessionid=2B2D46EB21CE0CC25367A0D788A1C916;jsessionid=E3ABCC38B2DFB44B1D6D02FE29D50CDD